PNC-27 acetate, a chimeric p53-penetratin peptide binds to HDM-2 in a p53 peptide-like structure, induces selective membrane-pore formation and leads to cancer cell lysis. PNC-27 acetate is an anticancer peptide. PNC-27 acetate can be used in acute myeloid leukemia research.
PNC-27 (50 μg/mL; 0-3 h) acetate induces cancer cell death[1].PNC-27 (50 μg/mL; 15 min) acetate binds to cell membrane-bound HDM-2 in A2058 and MCF-7 cells[1].
PNC-27 (intraperitoneal injection; 40 mg/kg; once daily; 2-3 w) acetate shows anti-leukemia activity in mice[2].
References:
[1]. Sarafraz-Yazdi E, et al. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):1918-23.
[2]. Wang H, et al. Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia. Leukemia. 2020 Jan;34(1):75-86.
[3]. Ehsan Sarafraz-Yazdi, et al. PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis. Biomedicines. 2022 Apr 20;10(5):945.